معرفی
Sheri L. Holmen, PhD is a Professor at the University of Utah School of Medicine, with an adjunct appointment in the Department of Oncological Sciences. She serves as a principal investigator at the Huntsman Cancer Institute (HCI) and co-director of the Melanoma Disease Oriented Research Team (MDOT).
- Academic Affiliations: Department of Surgery; Oncological Sciences (adjunct); Cell Response and Regulation Program, Molecular Biology Graduate Program
- Research Focus: Glioma, melanoma, mouse models of cancer, oncogenes, tumor suppressor genes
Her research employs RCAS/TVA retroviral models to investigate:
- Mechanisms of melanoma and glioma progression
- Role of AKT, BRAF, and IDH1 mutations
- Therapeutic targeting of focal adhesion kinase (FAK) and OXPHOS pathways
- Drug resistance mechanisms in MAPK-inhibitor therapies
Recent publications highlight:
- Combination therapies overcoming BRAF V600E melanoma resistance (2025)
- OXPHOS-driven melanoma metastasis biology (2025)
- Epigenetic profiling of stage II/III melanomas (2024)
- Sex-based differences in preclinical melanoma models (2020)
Scientific Awards:
- Karen H. Huntsman Presidential Endowed Chair (2019)
- Estela Medrano Memorial Award (2019)
- American Cancer Society Research Scholar (2006)
She leads the Holmen Lab, a multidisciplinary team working on biochemical, genetic, and in vivo approaches to cancer research.
۰مقاله منتشرشده
